about
Can the Treatment of Hypertension in the Middle-Aged Prevent Dementia in the Elderly?Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.Management of patients with type 2 diabetes and multiple chronic conditions: A Delphi consensus of the Spanish Society of Internal Medicine.Management of hypertension in diabetic patients: outstanding issues.Ambulatory blood pressure in stroke and cognitive dysfunction.Antithrombotic treatment in elderly patients with atrial fibrillation.Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management: differences between the European and American Guidelines.What's new in heart failure in the patient with type 2 diabetes?Ambulatory blood pressure monitoring in heart failure and serum sodium levels.[Vasoactive and inotropic drugs in acute heart failure].Postoperative hyperglycaemia control reduces postoperative complications in patients subject to total knee arthroplasty.Choosing an antihypertensive combination with a more efficient central blood pressure reduction.Erratum: Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].[Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC) on the 2012 European Cardiovascular Prevention Guidelines].High blood pressure, Alzheimer disease and antihypertensive treatment.Hypertension and mild cognitive impairment.Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.[2010. What novelties are there in vascular risk?].Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its Spanish acronym) on the 2012 European Cardiovascular Prevention Guidelines.Hyponatremia and benzodiazepines result in rhabdomyolysis.[Hypertension and dementia: A complex relationship].[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice.Misdiagnosis of resistant hypertension: Real frequency of true resistant hypertension in patients with suspected resistance to treatment.Is heart failure with midrange ejection fraction similar to preserved ejection fraction? For.[Integral control of risk factors in patients of high and very high cardiovascular risk in Spain. CIFARC project].Prevalence of masked hypertension and associated factors in normotensive healthcare workers.HBPF: a Home Blood Pressure Framework with SLA guarantees to follow up hypertensive patientsHBPF: a Home Blood Pressure Framework with SLA guarantees to follow up hypertensive patientsClinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine[Spanish Adaptation of the 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice]Prevalencia de hipertensión arterial enmascarada en una cohorte de pacientes hipertensos controlados en EspañaFactores asociados con la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivosSupervivencia a largo plazo del ictus isquémicoDenervación renal como tratamiento de la hipertensión arterial resistenteMicroscopic poliangiitis and human immunodeficiency virus infectionInfluence of admission blood pressure on mortality in patients with acute decompensated heart failure
P50
Q31076577-0F838998-D5C7-4354-A66F-B813EF7FECD9Q33427274-F74A70A9-F8CD-4094-A094-E422B849C289Q33692355-E828A6EB-40F3-4471-B08B-83829C9D0B12Q35846731-961D0334-3785-4DE7-A0B4-BA4FFD088082Q37895680-F61D4ED0-26F8-46CF-9EEC-689AEBE30CA3Q38098077-4696630F-73EF-46ED-9D43-B5C28AF245CEQ38331183-19EB86FE-D4FA-4044-ACE6-075C54EACE89Q38462359-0F59C10B-19E2-4FFF-A836-CCE38641FE3FQ38558113-59BB0586-1069-4030-A518-3A923169A574Q38695522-73474A4D-2D84-463E-AF05-0781AEA44C18Q39205497-CB5737A4-ACC2-4AE9-87CF-4EFC4C725681Q40444919-ADC0F5E2-B4D4-42A0-890E-7D48B168DA6CQ42797043-E13ADB18-0E5E-4AAB-99F8-2AE39B27B304Q43162976-29D80206-DE9D-4873-89E6-AD0643072CCEQ44848821-2EF6E2CA-2523-4E8B-88B9-740B637623F2Q46315596-A094D446-7C72-4B42-B4EC-34C8C718FF89Q47553627-76379023-15C8-482F-8695-521A76807F6CQ48333067-603FA78A-A986-4A90-905C-E86BE40B633AQ51001540-E8C0B9D4-C5BC-4E91-BCCA-EBC03B1D8201Q51031006-4CB7D672-7BDB-4267-A945-3DD3657815FEQ51168129-064ED5E6-CF93-4F03-A2E8-AA7C42D8E92BQ51170626-7DC9CE85-ED31-43AB-84AB-FBD524101594Q51624118-2BD18C60-3357-4EA0-B8D1-AD25B5AC2C5CQ53419345-9A7C3ABC-4D90-4DEA-A8A0-11BC8B85391EQ53644337-591095F8-CF30-4861-8FBB-48B59B398D25Q53663122-D3D41593-A2C9-483C-98E2-B3E2F193B05DQ53730190-66AA2714-B39C-46E8-9B80-62F13B057E34Q53841405-6092AD37-521D-4B4E-AB78-4EEDC94D384DQ54311757-8302E07B-C0F6-4FD2-9083-5485B3816447Q54658212-E302F887-AE43-448A-8B6C-D7FC6DCE8C36Q57000537-10C4EA65-F678-4E17-9668-D65064DEF651Q57000542-695F6FF3-E0AF-4AC3-9D1F-99EEE954C7BEQ57212357-82038313-87F9-42B7-ADDD-526A7D4F56DFQ57235750-1347AE3B-5172-49FE-9C7C-5CDDD5990828Q58210814-31EB5CC1-369F-4DB3-8EBB-6BB39A08EB8BQ59780639-9F714377-08CF-4020-B39F-DFABA28149F3Q60720629-4473B71E-67ED-429A-B0FF-4352CDD042BAQ61455517-BE4A3002-FCF3-42C1-AD7F-8651C46C2816Q74453261-9E7DFD26-EEC5-47E4-A053-CC91572677DEQ82414468-BA96C642-75E6-466C-A3C8-E8BF5311E17A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miguel Camafort-Babkowski
@ast
Miguel Camafort-Babkowski
@en
Miguel Camafort-Babkowski
@es
Miguel Camafort-Babkowski
@nl
Miguel Camafort-Babkowski
@sl
type
label
Miguel Camafort-Babkowski
@ast
Miguel Camafort-Babkowski
@en
Miguel Camafort-Babkowski
@es
Miguel Camafort-Babkowski
@nl
Miguel Camafort-Babkowski
@sl
altLabel
Miguel Camafort
@en
prefLabel
Miguel Camafort-Babkowski
@ast
Miguel Camafort-Babkowski
@en
Miguel Camafort-Babkowski
@es
Miguel Camafort-Babkowski
@nl
Miguel Camafort-Babkowski
@sl
P108
P1053
H-6310-2014
P106
P108
P1153
16635030900
P21
P31
P3829
P3835
miguel-camafort
P496
0000-0002-8669-6410